Evidence map›Paper›PMID 29948618›Full record

ArticlePathology oncology research : POR2020

Assessment of the circulating klotho protein in lung cancer patients.

Judit Pako, Andras Bikov, Imre Barta, Hideyo Matsueda, Rita Puskas, Gabriella Galffy, Anna Kerpel-Fronius, Balazs Antus, Ildiko Horvath

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Preeclampsia as a Study Model for Aging: The Klotho Gene Paradigm.International journal of molecular sciences · 2025
    Review
  2. Association ofInternational journal of molecular sciences · 2025
    Article
  3. Article
  4. [Research Progress of Klotho in Lung Neoplasms].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Role of Fibroblast Growth Factor 23 (FGF23) and αKlotho in Cancer.Frontiers in cell and developmental biology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Judit PakoNational Koranyi Institute of Pulmonology, Piheno ut 1, Budapest, 1121, Hungary. tidujok@gmail.com.ORCID http://orcid.org/0000-0002-8599-8986
Andras BikovDepartment of Pulmonology, Semmelweis University, Dios arok utca 1/c, Budapest, 1125, Hungary.
Imre BartaNational Koranyi Institute of Pulmonology, Piheno ut 1, Budapest, 1121, Hungary.
Hideyo MatsuedaSaitama Medical University Medical Center, 1981 Kamoda, Kawagoe-shi, Saitama, Japan.
Rita PuskasDepartment of Pulmonology, Semmelweis University, Dios arok utca 1/c, Budapest, 1125, Hungary.
Gabriella GalffyDepartment of Pulmonology, Semmelweis University, Dios arok utca 1/c, Budapest, 1125, Hungary.
Anna Kerpel-FroniusNational Koranyi Institute of Pulmonology, Piheno ut 1, Budapest, 1121, Hungary.
Balazs AntusNational Koranyi Institute of Pulmonology, Piheno ut 1, Budapest, 1121, Hungary.
Ildiko HorvathNational Koranyi Institute of Pulmonology, Piheno ut 1, Budapest, 1121, Hungary.
Országos Korányi Tbc és Pulmonológiai Intézet · HUSemmelweis University · HUSaitama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The anti-aging factor, klotho has been identified as a tumor suppressor in various human cancers, including lung cancer. In vitro studies provided evidence that klotho expression influences the characteristics of lung cancer cells, however, in vivo results are lacking. The aim of our study was to evaluate whether circulating klotho protein might serve as a potential biomarker of lung cancer. Blood samples were taken from 45 newly diagnosed lung cancer patients (31 NSCLC, 14 SCLC) and 43 control subjects. Plasma klotho concentration was measured using ELISA. No difference in plasma klotho values was detected between patients and control subjects (366.3 (257.9-486.8) vs. 383.5 (304.6-489.7) pg/ml respectively (median (IQR)); p > 0.05). Plasma klotho levels in patients with distant metastasis did not differ from less advanced stage disease (354.2 (306.9-433.3 vs. 328.5 (242.5-419.7) pg/ml, p > 0.05). In contrast, analyzed with one-way ANOVA, significant difference (p = 0.04) was found between the examined histological types of lung cancer: adenocarcinoma (353 (329.4-438.5) pg/ml), squamous cell carcinoma (308 (209.6-348.1) pg/ml) and small cell lung cancer (388.8 (289.9-495.4) pg/ml). However, Tukey's post hoc test did not reveal significant difference between any pairs of histological groups. There was no difference between any histological subtype and health either. Our results suggest that circulating klotho protein cannot be considered as a biomarker for lung cancer. Further studies are warranted in order to examine the relationship between klotho expression in lung tissue and circulating levels of the protein, and to explore its mechanism of action in lung cancer.

Indexed as

AgedBiomarkers, TumorCarcinoma, Non-Small-Cell LungFemaleGlucuronidaseHumansKlotho ProteinsLung NeoplasmsMaleMiddle AgedSmall Cell Lung CarcinomaBiomarkers, TumorGlucuronidaseKlotho ProteinsBiomarkersInsuline-like growth factor 1Lung cancerPremature agingTumor suppressor

Identifiers

PMID29948618
OpenAlexW2807912034

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.